当前位置:首页 >财报库 > 报告详情

山德士Sandoz 2025年上半年财报-净销售额「瑞士证券交易所」(英文版)(40页).pdf

上传人: 1****1 编号:915780 2025-09-19 40页 2.40MB

下载:

1、August 7,2025H1 2025 resultsDisclaimerThis presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of managements views and assumptions regarding future events and business performance at the time the statemen

2、ts are made.They are subject to risks and uncertainties including,but not confined to,future global economic conditions,exchange rates,legal provisions,market conditions,activities by competitors and other factors outside of the control of Sandoz.Should one or more of these risks or uncertainties ma

3、terialize or should underlying assumptions prove incorrect,actual outcomes may vary materially from those forecasted or expected.Each forward-looking statement speaks only as of the date of the particular statement,and Sandoz undertakes no obligation to publicly update or revise any forward-looking

4、statements,except as required by law.This presentation includes non-IFRS financial measures as defined by Sandoz.An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2025.Certain figures contained in this presentation,including financial

5、 information presented in billions or millions,certain operating data and percentages describing financial information or market shares,have been subject to rounding.Dollar values and percentages may not agree to totals.H1 2025 results 2AgendaDocument title31.Highlights and business updateRichard Sa

6、ynor,CEO Financial performance and guidanceRemco Steenbergen,CFO Wrap-up Richard Saynor,CEOQ&ARichard Saynor,CEO|Remco Steenbergen,CFO 2.3.4.Highlights and business updateRichard SaynorChief Executive OfficerStrong progress in first half of yearH1 2025 results 51Additional manufacturing capabili

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
- **业绩亮点与业务更新**:Sandoz在2025年上半年取得显著进展,包括在斯洛文尼亚新增制造能力,并计划收购Just-Evotec Biologics EU SAS,以建立全球端到端生物类似物平台。 - **财务表现与展望**:2025年上半年核心稀释每股收益增长33%,自由现金流超过10亿美元。全年净销售额增长预计为低个位数,核心EBITDA利润率约为21%。 - **生物类似物增长**:Pyzchiva和Tyruko在欧洲和美国的成功推出推动了生物类似物业务的强劲增长。 - **全球生物类似物管线**:Sandoz拥有领先的生物类似物管线,包括Pyzchiva、Pyzchiva自动注射剂、Wyost和Jubbonti等。 - **全球市场表现**:Sandoz在全球范围内取得良好表现,包括在欧洲和美国的生物类似物市场以及国际市场的Omnitrope。 - **未来展望**:Sandoz将继续投资于长期发展,并计划在下半年推出更多产品,以实现全年指导目标。
生物类似药市场增长如何?" "2025上半年,Sandoz业绩亮点有哪些?" "Sandoz未来生物类似药管线展望如何?"
客服
商务合作
小程序
服务号
折叠